Skip to main content

Judith Mae Kramer

Professor Emeritus of Medicine
Medicine, General Internal Medicine
Box 3850 Med Ctr, Durham, NC 27710
2400 Pratt St, Durham, NC 27705

Overview


· Studying methods to facilitate the uptake of evidence-based treatment recommendations.
· Optimizing the use of drugs, devices, and biological products in clinical practice.
· Studying methods of risk management for therapeutic products

Current Appointments & Affiliations


Professor Emeritus of Medicine · 2014 - Present Medicine, General Internal Medicine, Medicine
Member in the Duke Clinical Research Institute · 1997 - Present Duke Clinical Research Institute, Institutes and Centers

In the News


Published May 27, 2016
FDA approves new way to treat opioid addiction -- under the skin
Published January 14, 2016
Dr. Judith Kramer comments: Panel recommends FDA approve implant to treat opiate addiction

View All News

Recent Publications


Industry Practices for Expedited Reporting to Investigators Conducting Research Under an IND.

Journal Article Ther Innov Regul Sci · November 2014 Due to investigators' complaints about the volume and limited interpretability of expedited safety reports received in Investigational New Drug (IND) studies, the authors surveyed industry sponsors in late 2009 about their reporting practices. An Internet- ... Full text Link to item Cite

Investigators' Experience With Expedited Safety Reports Prior to the FDA's Final IND Safety Reporting Rule.

Journal Article Ther Innov Regul Sci · July 2014 Prior to enactment of the final investigational new drug application (IND) safety reporting rule, an attempt was made to document the effort expended at investigative sites in processing IND safety reports from sponsors and to assess the effect of these ex ... Full text Link to item Cite

Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug Application.

Journal Article Ther Innov Regul Sci · March 2014 In September 2010, the US Food and Drug Administration (FDA) published a final rule governing the requirements for expedited safety reporting for products subject to an investigational new drug application. The rule clarified the types of safety informatio ... Full text Link to item Cite
View All Publications

Recent Grants


CTTI U19

ResearchProgram Director · Awarded by Food and Drug Administration · 2009 - 2015

Duke Cardiovascular CERTs

ResearchCo Investigator · Awarded by Agency for Healthcare Research and Quality · 2007 - 2012

Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease

ResearchCo-Mentor · Awarded by National Institutes of Health · 2006 - 2011

View All Grants

Education, Training & Certifications


University of North Carolina, Chapel Hill · 1977 M.D.
University of North Carolina, Chapel Hill · 1972 M.S.
University of North Carolina, Chapel Hill · 1970 B.S.